Transcatheter Mitral Valve Repair and Replacement Market Analysis Report, Regional Outlook with Key Players - Abbott Laboratories, Colibri Heart Valve, Edward Lifesciences, HLT Medical, LivaNova, Medtronic, Neovasc, NeoChord

Coherent Market Insights has announced the addition of the “Transcatheter Mitral Valve Repair and Replacement Market Size Status and Forecast 2026”, The report classifies the global Transcatheter Mitral Valve Repair and Replacement Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. This report focuses on the top players in global market, like Abbott Laboratories, Biotronik Private Limited, Colibri Heart Valve, Edward Lifesciences Corporation, HLT Medical, LivaNova Plc, Medtronic Plc, Neovasc Inc., and NeoChord.

Transcatheter mitral valve repair and replacement methods are gaining significant traction due to advances in valve therapy. Transcatheter Mitral Valve Replacement (TMVR) can be used as an alternative to open-heart surgery and is used in treating mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2189

Increasing mortality due to chronic and cardiovascular diseases especially in the elderly population is a major factor boosting the growth of the market. As per the American Heart Association estimates in 2017, around 19.1 million death occur annually worldwide due to various cardiovascular diseases. Furthermore, as per the United Nations (UN) estimates 2017, the geriatric population in the U.S. is expected to reach over 72 million by 2022. The growth of this target population coupled with increasing risk of cardiovascular diseases is expected to drive the growth of the market.
The global transcatheter mitral valve repair and replacement devices market is expected to witness growth, owing to continuous technological advancements such as developing multiple use valves. For instance, in June 2017, Edwards Lifesciences received FDA approval for its SAPIEN 3 transcatheter prosthetic heart valve, indicated for placement within both mitral valves and aortic valves.

Increase in number of TMVR pipeline devices for treatment of mitral valve abnormalities are also expected to propel growth of TMVR market. For instance, a randomized clinical trial of Medtronic Intrepid Transcatheter Mitral Valve Replacement System, sponsored by Medtronic Cardiovascular is ongoing for treating mitral valve regurgitation and is estimated to complete in October 2025.

Transcatheter mitral valve repair and replacement methods are gaining major traction as the next major development in valve therapy; however, there are certain challenges that will need to be addressed, including complex technology design, delivery methods and identifying the most appropriate patient population to benefit from this technology. Further, advent of transcatheter mitral valve replacement devices is going to boost the global market in the forecast period. In the recent years, many start-up companies are dedicated in developing the optimal transcatheter mitral valve replacement technology, with major focus on the transapical delivery approach to further simplify the delivery method. Several medical device companies are now in competition to bring first-generation transcatheter mitral valves to market.

By Product Type

• Bioprosthetic Tissue (Biological) Valves
• Mechanical Valves

By Indication

• Mitral Valve Regurgitation
• Mitral Valve Stenosis
• Mitral Valve Prolapse

By End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Cardiac Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Africa
• Middle East

North America is projected to dominate transcatheter mitral valve repair and replacement market, owing to high prevalence of cardiac disease. For instance, in the U.S., heart disease is a leading cause of death, accounting for around 375,000 deaths annually. According to ClinicoEconomics and Outcomes Research 2016, Mitral regurgitation is the most frequent valve disease in the U.S. affecting nearly 1 in 10 people of 75 years or older.

Asia Pacific region is expected to witness significant growth, owing expansions of manufacturing facilities by market players. For instance, Medtronic, Inc. in March 2011, opened new manufacturing facility in Singapore to meet increasing demand for cardiac devices in region.

Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2189

What Information does this report contain?

-Historical data coverage: 2013 to 2017; Growth Projections: 2018 to 2026.
-Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
-6-7 year performance forecasts: major segments covering applications, top products and geographies.
-Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.